Chicago Equity Partners’s Integra LifeSciences IART Stock Holding History

Chicago Equity Partners’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-13,690	Closed	-$798K	–	758
2019 Q4	$798K	Hold	13,690	–	–	0.05%	521
2019 Q3	$822K	Buy	+13,690	New	+$816K	0.04%	551

Other funds holding IART

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Chicago Equity Partners's IART Position: Q1 2020 in Review

Chicago Equity Partners sold out of Integra LifeSciences (IART) in Q1 2020, closing a stake of 13,690 shares — an estimated $798K sold.

Chicago Equity Partners first reported a position in IART in Q3 2019 and held it in 2 quarters. The position peaked at $822K in Q3 2019. 258 funds tracked by Wall St. Rank hold IART as of Q1 2020.

Chicago Equity Partners reported no remaining Integra LifeSciences position as of Q1 2020 after selling out during the quarter.
Chicago Equity Partners sold 13,690 Integra LifeSciences shares in Q1 2020, an estimated $798K.
Chicago Equity Partners first reported a position in Integra LifeSciences in Q3 2019 and held it in 2 quarters.
Chicago Equity Partners's Integra LifeSciences position peaked at $822K in Q3 2019.
258 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.